BMS-708163 is a γ-secretase inhibitor that suppresses Notch signaling and exhibits neuroprotective activity. BMS-708163 decreases the formation of amyloid-β (Aβ) plaques and is in clinical trials as a potential treatment for Alzheimer’s disease.
| Cas No. | 1146699-66-2 |
|---|---|
| Purity | ≥98% |
| Formula | C20H17ClF4N4O4S |
| Formula Wt. | 520.88 |
| IUPAC Name | N2-[(4-Chlorophenyl)sulfonyl]-5,5,5-trifluoro-N2-[2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl]norvalinamide |
| Synonym | Avagacestat, BMS708163 |
| Solubility | DMSO Solubility: 104 mg/mL (199.66 mM) |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tong G, Castaneda L, Wang JS, et al. Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men. Clin Drug Investig. 2012 Nov;32(11):761-9. PMID: 23018285.
Gillman KW, Starrett JE Jr, Parker MF, et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. ACS Med Chem Lett. 2010 Mar 22;1(3):120-4. PMID: 24900185.
